Reule Scott, Sexton Donal J, Solid Craig A, Chen Shu-Cheng, Collins Allan J, Foley Robert N
Department of Medicine, University of Minnesota, Minneapolis, MN; United States Renal Data System, Minneapolis Medical Research Foundation, Minneapolis, MN.
United States Renal Data System, Minneapolis Medical Research Foundation, Minneapolis, MN.
Am J Kidney Dis. 2014 Oct;64(4):592-9. doi: 10.1053/j.ajkd.2014.05.020. Epub 2014 Aug 16.
Autosomal dominant polycystic kidney disease (ADPKD) is amenable to early detection and specialty care. Thus, while important to patients with the condition, end-stage renal disease (ESRD) from ADPKD also may be an indicator of the overall state of nephrology care.
Retrospective cohort study of temporal trends in ESRD from ADPKD and pre-renal replacement therapy (RRT) nephrologist care, 2001-2010 (n = 23,772).
SETTING & PARTICIPANTS: US patients who initiated maintenance RRT from 2001 through 2010 (n = 1,069,343) from US Renal Data System data.
ESRD from ADPKD versus from other causes for baseline characteristics and clinical outcomes; interval 2001-2005 versus 2006-2010 for comparisons of cohort of patients with ESRD from ADPKD.
Death, wait-listing for kidney transplant, kidney transplantation.
US census data were used as population denominators. Poisson distribution was used to compute incidence rates (IRs). Incidence ratios were standardized to rates in 2001-2002 for age, sex, and race/ethnicity. Patients with and without ADPKD were matched to compare clinical outcomes. Poisson regression was used to calculate IRs and adjusted HRs for clinical events after inception of RRT.
General population incidence ratios in 2009-2010 were unchanged from 2001-2002 (incidence ratio, 1.02). Of patients with ADPKD, 48.1% received more than 12 months of nephrology care before RRT; preemptive transplantation was the initial RRT in 14.3% and fistula was the initial hemodialysis access in 35.8%. During 4.9 years of follow-up, patients with ADPKD were more likely to be listed for transplantation (IR, 11.7 [95% CI, 11.5-12.0] vs 8.4 [95% CI, 8.2-8.7] per 100 person-years) and to undergo transplantation (IR, 9.8 [95% CI, 9.5-10.0] vs 4.8 [95% CI, 4.7-5.0] per 100 person-years) and less likely to die (IR, 5.6 [95% CI, 5.4-5.7] vs 15.5 [95% CI, 15.3-15.8] per 100 person-years) than matched controls without ADPKD.
Retrospective nonexperimental registry-based study of associations; cause-and-effect relationships cannot be determined.
Although outcomes on dialysis therapy are better for patients with ADPKD than for those without ADPKD, access to predialysis nephrology care and nondeclining ESRD rates may be a cause for concern.
常染色体显性遗传性多囊肾病(ADPKD)适合早期检测和专科护理。因此,虽然对患有该疾病的患者很重要,但ADPKD导致的终末期肾病(ESRD)也可能是肾脏病护理总体状况的一个指标。
对2001 - 2010年期间ADPKD导致的ESRD及肾替代治疗(RRT)前肾脏病专家护理的时间趋势进行回顾性队列研究(n = 23,772)。
根据美国肾脏数据系统数据,2001年至2010年开始维持性RRT的美国患者(n = 1,069,343)。
ADPKD导致的ESRD与其他原因导致的ESRD的基线特征和临床结局;2001 - 2005年与2006 - 2010年对ADPKD导致的ESRD患者队列进行比较。
死亡、等待肾移植、肾移植。
美国人口普查数据用作人群分母。采用泊松分布计算发病率(IR)。发病率比按2001 - 2002年的年龄、性别和种族/民族率进行标准化。对有和没有ADPKD的患者进行匹配以比较临床结局。采用泊松回归计算RRT开始后临床事件的IR和调整后的HR。
2009 - 2010年的总体人群发病率比与2001 - 2002年相比无变化(发病率比,1.02)。在患有ADPKD的患者中,48.1%在RRT前接受了超过12个月的肾脏病护理;抢先移植是14.3%患者的初始RRT,而内瘘是35.8%患者的初始血液透析通路。在4.9年的随访期间,与匹配的无ADPKD对照组相比,患有ADPKD的患者更有可能被列入移植名单(IR,每100人年11.7 [95% CI,11.5 - 12.0]对8.4 [95% CI,8.2 - 8.7]),更有可能接受移植(IR,每100人年9.8 [95% CI,9.5 - 10.0]对4.8 [95% CI,4.7 - 5.0]),且死亡可能性更小(IR,每100人年5.6 [95% CI,5.4 - 5.7]对15.5 [95% CI,15.3 - 15.8])。
基于回顾性非实验性登记研究的关联;无法确定因果关系。
虽然ADPKD患者的透析治疗结局优于无ADPKD患者,但透析前肾脏病护理的可及性和ESRD发病率无下降可能令人担忧。